# Morphine

## Morphine  inj 10mg/1mL

| 藥物代碼 | IMORP |
| :--- | :--- |
| 適應症 | Relief of moderate to severe pain. Pre-op anesth. |
| 副作用 | Nausea, vomiting, constipation, drowsiness, palpitations, headache, disorientation, vertigo, mood changes, decreased libido, ureteric spasm, urinary retention, rash, sweating, facial flushing, miosis. |
| 禁忌 | Respiratory depression, head injury, obstructive airways disease, paralytic ileus, GI obstruction, delayed gastric emptying, acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children &lt; 3 years. |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Human \(and animal\) data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IM, IVD, IVP, IVPUSH, SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【N/S】 可選  【D5W】 可選 |
| IVP 用法建議 | 推注時間至少4-5分鐘 |
| IVD 用法建議 | 起始劑量: 每3-4小時2.0-5mg，持續輸注: 0.8-10mg/hr；用呼吸器的病患\(以70kg計\)起始劑量:每1-2小時0.7-10mg，持續輸注:5-35mg/hr |
| 注意事項 | 1. IV給藥濃度0.5-3mg/mL，緩慢注射4-5分鐘。 |

## Morphine inj 10mg/1mL殘餘銷燬

| 藥物代碼 | IMORPBAD |
| :--- | :--- |
| 適應症 | NA |
| 副作用 | NA |
| 禁忌 | NA |
| 藥物保存方式 | N/A |
| 用法用量 | Adult:  PO: Initial, 10-30 mg q4h.  IM or SC:5-20 mg \(usually 10 mg\) q4h as needed.  IV \(only rarely\): 2.5-10 mg diluted in 4-5 ml of water for injection, administered slowly over 4-5 mins. Child:  SC:0.1-0.2 mg/kg, not to exceed 15 mg/dose. |
| 肝功能異常 | 無需調整劑量  需調整劑量 |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IM, IVD, IVP, IVPUSH |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Morphine 15mg

| 藥物代碼 | OMOR1 |
| :--- | :--- |
| 適應症 | Relief of moderate to severe pain. Pre-op anesth. |
| 副作用 | Nausea, vomiting, constipation, drowsiness, palpitations, headache, disorientation, vertigo, mood changes, decreased libido, ureteric spasm, urinary retention, rash, sweating, facial flushing, miosis.Cardiovascular: Peripheral edema \(5% to 10% \)Dermatologic: Pruritus \(up to 80% \), Rash \(5% to 10% \), Sweating \(5% to 10% \)Gastrointestinal: Abdominal pain \(5% to 10% \), Constipation \(&gt; 10% \), Diarrhea \(5% to 10% \), Loss of appetite \(5% to 10% \), Nausea and vomiting \(7% to 70% \), Xerostomia \(5% to 10% \)Hepatic: Liver function tests abnormal \(&lt; 5% \)Musculoskeletal: Backache \(5% to 10% \)Neurologic: Asthenia \(5% to 10% \), Dizziness \(6% \), Headache \(&gt;10% \), Insomnia \(5% to 10% \), Lightheadedness, Paresthesia \(5% to 10% \), Somnolence \(&gt; 10% \)Ophthalmic: Amblyopia \(&lt; 5% \), MiosisPsychiatric: Anxiety \(6% \), Depression \(5% to 10% \)Renal: Urinary retention \(oral: &lt; 5% ; epidural/intrathecal: 15% to 70% \)Other: Fever \(5% to 10% \), Hiccoughs \(&lt; 5% \) |
| 禁忌 | Respiratory depression, head injury, obstructive airways disease, paralytic ileus, GI obstruction, delayed gastric emptying, acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children &lt; 3 years. |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Human \(and animal\) data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Morphine 15mg 殘餘銷燬

| 藥物代碼 | OMOR1BAD |
| :--- | :--- |
| 適應症 | NA |
| 副作用 | NA |
| 禁忌 | NA |
| 藥物保存方式 | N/A |
| 用法用量 | N/A |
| 肝功能異常 | 無需調整劑量  需調整劑量 |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | N/A |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

